INVITED REVIEW SERIES: TUBERCULOSIS: CURRENT STATE OF KNOWLEDGE
Diagnosis and treatment of latent infection with Mycobacterium tuberculosis
Version of Record online: 25 JAN 2013
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology
Volume 18, Issue 2, pages 205–216, February 2013
How to Cite
CHEE, C. B.-E., SESTER, M., ZHANG, W. and LANGE, C. (2013), Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology, 18: 205–216. doi: 10.1111/resp.12002
The Authors: Cynthia B.-E. Chee, MBBS, FRCP, is senior consultant respiratory physician at the Tuberculosis Control Unit and Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore. Her research interests are clinical and public health aspects of TB. Martina Sester, PhD, is a Professor of Transplant and Infection Immunology at Saarland University, Germany, and her research interests focus on the characterization of cellular immune responses for the control of clinically relevant pathogens. Wenhong Zhang, MD, PhD, is a Professor of Medicine at Fudan University, China. He is the director of the Department of Infectious Diseases. His research interests include diagnosis and treatment of infectious diseases, especially TB. Christoph Lange, Dr. med. Dipl.-Biol, FIDSA, is a Professor of Medicine at the University of Lübeck, Germany. At the Research Center Borstel, Germany, he is the principal attending physician of the Medical Clinic and the Head of the Division of Clinical Infectious Diseases. His research interests include topics of the prevention, diagnosis and treatment of TB.
Conflict of Interest Statement: MS and CL have received kits free of charge from Cellestis and Oxford Immunotec to study the performance of interferon-γ release assay responses in immune-compromised patients. CL has conducted investigator-initiated clinical trials, where QuantiFERON-TB Gold In-Tube and T-SPOT.TB test kits were provided by the manufacturers free of charge. MS has a patent application entitled ‘In vitro process for the quick determination of a patient's status relating to infection with Mycobacterium tuberculosis’ (international patent number WO2011113953/A1).
SERIES EDITORS: CHI CHIU LEUNG, CHRISTOPH LANGE AND YING ZHANG
- Issue online: 25 JAN 2013
- Version of Record online: 25 JAN 2013
- Accepted manuscript online: 29 OCT 2012 04:42AM EST
- Manuscript Accepted: 12 OCT 2012
- Manuscript Received: 29 SEP 2012
- 1World Health Organization. Tuberculosis. Fact sheet °104. 2012. [Accessed 9 Sep 2012.] Available from URL: http://www.who.int/mediacentre/factsheets/fs104/en/
- 23Tuberculosis in the immunocompromised host. Eur. Resp. Monograph 2012 (in press)., , et al.
- 48Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC), 2nd edn. Tuberculosis Coalition for Technical Assistance, The Hague, 2009.
- 49World Health Organization. WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. World Health Organization, Geneva, 2012.
- 55International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull. World Health Organ. 1982; 60: 555–564.
- 58American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 2000; 49: 1–51.
- 66National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011. [Accessed 15 Nov 2012.] Available from URL: http://guidance.nice.org.uk/CG117/NICEGuidance/pdf/English
- 68A randomized clinical trial comparing 4RIF vs 9INH for treatment of latent tuberculosis infection (LTBI)—effectiveness. 2012. [Accessed 10 Sep 2012.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00931736.
- 71The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin. Infect. Dis. 2007; 45: 715–722., , et al.
- 75Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283: 1445–1450., , et al.
- 76American Thoracic Society/Centers of Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb. Mortal. Wkly Rep. 2003; 52: 735–739.
- 80Centers of Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb. Mortal. Wkly Rep. 2011; 60: 1650–1653.
- 86World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. World Health Organization, Geneva, 2011.
- 90Centers of Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm. Rep. 1992; 41: 61–71.
- 94Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edn. Curry International Tuberculosis Centre, California Department of Public Health, San Francisco, CA, 2008.
- 96Stop TB Partnership Childhood TB subgroup. Chapter 4: childhood contact screening and management. Int. J. Tuberc. Lung Dis. 2007; 11: 12–15.
- 97European Centre for Disease Prevention and Control. Management of Contacts of MDR TB and XDR TB Patients. ECDC, Stockholm, 2012.